These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8481406)

  • 1. The activity of wheat gliadin peptides in in vitro assays for coeliac disease.
    Cornell HJ; Mothes T
    Biochim Biophys Acta; 1993 Apr; 1181(2):169-73. PubMed ID: 8481406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further studies of the in vitro activity of synthetic gliadin peptides in coeliac disease.
    Cornell H; Mothes T
    Biochim Biophys Acta; 1995 Apr; 1270(2-3):168-72. PubMed ID: 7727540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid composition of gliadin fractions which may be toxic to individuals with coeliac disease.
    Cornell HJ; Maxwell RJ
    Clin Chim Acta; 1982 Aug; 123(3):311-9. PubMed ID: 6811164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the gliadin-derived peptides which are biologically active in coeliac disease.
    Cornell H; Wieser H; Belitz HD
    Clin Chim Acta; 1992 Dec; 213(1-3):37-50. PubMed ID: 1477986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of in vitro gamma-interferon production in coeliac disease as a response to gliadin peptides.
    Cornell HJ; Skerritt JH; Puy R; Javadpour M
    Biochim Biophys Acta; 1994 May; 1226(2):126-30. PubMed ID: 8204658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of gliadin peptides on rat-liver lysosomes in relation to the pathogenesis of coeliac disease.
    Cornell HJ; Townley RR
    Clin Chim Acta; 1973 Dec; 49(2):181-8. PubMed ID: 4589526
    [No Abstract]   [Full Text] [Related]  

  • 7. The precipitating factor in coeliac disease.
    Wieser H
    Baillieres Clin Gastroenterol; 1995 Jun; 9(2):191-207. PubMed ID: 7549024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acid composition of peptides remaining after in vitro digestion of a gliadin sub-fraction with duodenal mucosa from patients with coeliac disease.
    Cornell HJ
    Clin Chim Acta; 1988 Sep; 176(3):279-89. PubMed ID: 3180479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships in coeliac-toxic gliadin peptides.
    Cornell HJ; Wills-Johnson G
    Amino Acids; 2001; 21(3):243-53. PubMed ID: 11764405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural specificities and significance for coeliac disease of wheat gliadin peptides able to agglutinate or to prevent agglutination of K562(S) cells.
    De Vincenzi M; Stammati A; Luchetti R; Silano M; Gasbarrini G; Silano V
    Toxicology; 1998 May; 127(1-3):97-106. PubMed ID: 9699797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between gliadin peptide structure and their effect on the fetal chick duodenum.
    Kocna P; Mothes T; Krchnák V; Fric P
    Z Lebensm Unters Forsch; 1991 Feb; 192(2):116-9. PubMed ID: 2014713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between gliadin structure and coeliac toxicity.
    Wieser H
    Acta Paediatr Suppl; 1996 May; 412():3-9. PubMed ID: 8783747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The toxic fraction of gliadin digests in coeliac disease. Isolation by chromatography on Biogel P-10.
    Jos J; Charbonnier L; Mossé J; Olives JP; de Tand MF; Rey J
    Clin Chim Acta; 1982 Mar; 119(3):263-74. PubMed ID: 6802520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coeliac disease: characterisation of monoclonal antibodies raised against a synthetic peptide corresponding to amino acid residues 206-217 of A-gliadin.
    Ellis HJ; Doyle AP; Sturgess RP; Ciclitira PJ
    Gut; 1992 Nov; 33(11):1504-7. PubMed ID: 1280610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxic effect of wheat gliadin-derived peptides on the Caco-2 intestinal cell line is associated with intracellular oxidative imbalance: implications for coeliac disease.
    Rivabene R; Mancini E; De Vincenzi M
    Biochim Biophys Acta; 1999 Jan; 1453(1):152-60. PubMed ID: 9989255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of extended amino acid motifs for focussing on toxic peptides in coeliac disease.
    McLachlan A; Cullis PG; Cornell HJ
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):319-24. PubMed ID: 12385967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of reactive synthetic gliadin peptides specific for coeliac disease.
    Devery JM; Bender V; Penttila I; Skerritt JH
    Int Arch Allergy Appl Immunol; 1991; 95(4):356-62. PubMed ID: 1720424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of wheat gliadin fractions in coeliac disease.
    Townley RR; Cornell HJ; Bhathal PS; Mitchell JD
    Lancet; 1973 Jun; 1(7816):1363-4. PubMed ID: 4122746
    [No Abstract]   [Full Text] [Related]  

  • 19. Wheat peptide challenge in coeliac disease.
    Sturgess R; Day P; Ellis HJ; Lundin KE; Gjertsen HA; Kontakou M; Ciclitira PJ
    Lancet; 1994 Mar; 343(8900):758-61. PubMed ID: 7907731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis in caco-2 cells by wheat gliadin peptides.
    Giovannini C; Sanchez M; Straface E; Scazzocchio B; Silano M; De Vincenzi M
    Toxicology; 2000 Apr; 145(1):63-71. PubMed ID: 10771132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.